Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引：0

作者：

Almadani, Ahmad H. ^{[1
,2
]}

Alhadi, Ahmad N. ^{[1
,2
,3
]}

Aldawood, Buthainah D. ^{[4
]}

Aleissa, Mariam M. ^{[5
,6
]}

Alosaimi, Fahad D. ^{[1
,2
]}

机构：

[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia

[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia

[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia

[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia

[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia

[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia

来源：

SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES | 2025年 / 13卷 / 01期

关键词：

Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;

D O I：

10.4103/sjmms.sjmms_306_24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.

引用

页码：1 / 6

页数：6

共 50 条

[31] Contralateral Prophylactic Mastectomy: What Do We Know and What Do Our Patients Know?
Khan, Seema A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2132 - 2135
[32] Pulmonary arterial hypertension in SLE: what do we know?
Prabu, A.
Gordon, C.
LUPUS, 2013, 22 (12) : 1274 - 1285
[33] Ticks and Tularemia: Do We Know What We Don't Know?
Zellner, Briana
Huntley, Jason F.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
[34] What Do We Know About Suicidality in Autism Spectrum Disorders? A Systematic Review
Segers, Magali
Rawana, Jennine
AUTISM RESEARCH, 2014, 7 (04) : 507 - 521
[35] What do we know about delusional misidentification disorders? A focus on Capgras syndrome
Iftikhar, Bushra
Baweja, Ramneesh
Tatugade, Aniket
Scarff, Jonathan R.
Lippmann, Steven
NEUROPSYCHIATRY, 2012, 2 (02) : 111 - 116
[36] Epidemiology of MPN: What Do We Know?
Anderson, L. A.
McMullin, M. F.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) : 340 - 349
[37] Epidemiology of MPN: What Do We Know?
L. A. Anderson
M. F. McMullin
Current Hematologic Malignancy Reports, 2014, 9 : 340 - 349
[38] Cancer and stroke: What do we know and where do we go?
Lun, Ronda
Siegal, Deborah
Ramsay, Tim
Dowlatshahi, Dar
THROMBOSIS RESEARCH, 2022, 219 : 133 - 140
[39] The Public Stigma of Mental Illness: What Do We Think; What Do We Know; What Can We Prove?
Pescosolido, Bernice A.
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 2013, 54 (01) : 1 - 21
[40] The Future of Exertional Respiratory Problems What Do We Know About the Total Airway Approach and What Do We Need to Know?
Olin, J. Tod
Hull, James H.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2018, 38 (02) : 333 - +

← 1 2 3 4 5 →